PureTech Health plc (PRTC) News & Overview - Discounting Cash Flows
PRTC
PureTech Health plc
PRTC (NASDAQ)

PRTC's Business Model

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Sector & Industry Healthcare / Biotechnology
Website https://www.puretechhealth.com
CEO (Chief Executive Officer) Bharatt M. Chowrira
Number of Employees
IPO date November 16, 2020

PRTC Latest News

Contact
CountryUS
Address6 Tide Street
CityBoston
StateMA
Phone617 482 2333
Zip Code02210
Other Identifiers
CIK0001782999
ISINUS7462371060
CUSIP746237106
Open17.6
Previous Close18.01
Volume954
Average Volume4.45 Thou.
Day’s Range17.475 – 18.08
52 Week Range13.3-25
MA (50)17.8616
MA (200)18.94757
Market Cap434.3 Mil.
Shares Out.24.02 Mil.
Earnings DateJul 30, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for PRTC

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us